Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku.
BACKGROUND
The management of a pregnant woman with the rare Ko phenotype and anti-Ku is a special challenge, because matched blood is extremely rare and the possibility of severe hemolytic disease of the newborn is high.


METHODS
A 30-year-old woman with rare Ko (Knull) phenotype presented at 18 weeks of gestation with positive indirect agglutination test results. She had anti-Ku due to previous blood transfusion, one pregnancy, and two abortions.


METHODS
During this pregnancy, anti-Ku titers ranged from 1024 to 4096. At the 26th week of gestation ultrasound showed a hydropic fetus and urgent intrauterine exchange transfusion was performed with the maternal red blood cells (RBCs). Recombinant human erythropoietin (rHu-EPO) and intravenous (IV) iron were administered to the mother to ensure an adequate supply of matched RBCs for intrauterine transfusions and possible perinatal hemorrhage.


RESULTS
Intrauterine transfusions were repeated every 1 to 3 weeks. By 35 weeks 2 days of gestation, the mother had donated 4 units of blood, and four intrauterine transfusions had been performed. Cesarean section was then decided and a healthy male newborn was born. He was treated with phototherapy but without exchange transfusions. By the 15th day of life rHu-EPO was administrated to the newborn because of anemia. The maternal RBCs completely disappeared from the child's blood by Day 100.


CONCLUSIONS
As shown in this case, treatment with rHu-EPO and IV Fe has effectively increased the mother's capacity to donate RBCs for autologous use and intrauterine transfusions, with no adverse effects to the mother or the child.
Lydaki
Evaggelia
E
Department of Transfusion Medicine, University Hospital of Heraklion, Crete, Greece. xatzakis@her.forthnet.gr
Nikoloudi
Irene
I
Kaminopetros
Petros
P
Bolonaki
Irene
I
Sifakis
Stavros
S
Kikidi
Katerina
K
Koumantakis
Evgenios
E
Foundouli
Kaliopi
K
D000328:Adult; D000743:Anemia, Hemolytic / Q000188:drug therapy / Q000276:immunology; D034961:Antigens, Nuclear / Q000276:immunology*; D001782:Blood Donors; D001805:Blood Transfusion, Intrauterine; D002585:Cesarean Section; D004268:DNA-Binding Proteins / Q000276:immunology*; D004899:Erythroblastosis, Fetal / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies / Q000097:blood; D007626:Kell Blood-Group System / Q000276:immunology; D000072200:Ku Autoantigen; D008297:Male; D011247:Pregnancy / Q000097:blood*; D011994:Recombinant Proteins; D012720:Severity of Illness Index
D034961:Antigens, Nuclear; D004268:DNA-Binding Proteins; D007518:Isoantibodies; D007626:Kell Blood-Group System; D011994:Recombinant Proteins; D004921:Erythropoietin; C000606509:Xrcc6 protein, human; D000072200:Ku Autoantigen